Most relapsing MS patients on Mavenclad did not have confirmed disability progression for at least four years, new Phase 4 ...

Treatment with Sanofi's frexalimab was seen in a study to safely maintain disease control over 2.5 years in adults with ...

Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...

Psychological therapies are effective for people with multiple sclerosis, showing benefits across mental health, cognitive function, physical well-being, and quality of life.

The drugmaker has launched an international Phase I trial, dubbed Breakfree-2, in seven countries to test the autologous therapy.

A study led by Case Western Reserve University (CWRU) shows new potential for treating multiple sclerosis (MS) and other ...

A combination of metformin, a common diabetes drug, and clemastine, an antihistamine, can help repair myelin—the protective ...

Compared with low physical activity, the risk of confirmed disability worsening was reduced for people with moderate (HR 0.82, 95% CI 0.71-0.94), moderate-high (HR 0.72, 95% CI 0.61-0.86), and high ...

Insights from ECTRIMS 2025, including anticipated presentations, key takeaways, and how emerging research on DMTs in RRMS may ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic ...